Nanobiotix S.A. (0QAV.L) LSE
43.40
+3.2(+7.96%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
43.40
+3.2(+7.96%)
Currency In EUR
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
108
First IPO Date
February 13, 2014
| Name | Title | Pay | Year Born |
| Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer | 844,959 | 1973 |
| Anne-Juliette Hermant | Chief People Officer & Member of Executive Board | 414,440 | 1974 |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | 600,232 | 1974 |
| Louis Kayitalire | Chief Medical Officer & Member of Executive Board | 603,196 | 1959 |
| Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | 0 | N/A |
| Brandon Owens | Vice President of Strategic Marketing & Corporate Communication | 0 | N/A |
| Earl J. Bergey | Co-Founder | 0 | 1955 |
| Margaret Galluzzi | Vice President & Global Head of Clinical Operations | 0 | N/A |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.